Health Care • Medical/Dental Instruments
$60.53 ▲ +1.43
(+2.42%)
MKT CAP: $5.26B • VOL: 1.30M
52W L $20 52W H $61
HTFL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $176.0M | $125.8M | $87.2M |
| YoY Revenue Growth % | +39.9% | +44.3% | — |
| Gross Profit | $135.2M | $94.4M | $38.4M |
| Gross Margin % | 76.8% | 75.1% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$64.1M | -$61.2M | -$72.9M |
| Operating Margin % | -36.4% | -48.7% | -83.6% |
| Net Income (GAAP) | -$116.8M | -$96.4M | -$95.7M |
| EBITDA (Normalized) | -$60.0M | -$57.7M | -$69.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$54.0M | -$69.0M | -$76.4M |
| Capital Expenditures (CapEx) | $5.0M | $4.4M | $3.9M |
| Free Cash Flow (FCF) | -$59.0M | -$73.4M | -$80.4M |
| FCF Margin % | -33.5% | -58.3% | -92.2% |
| Return on Invested Capital (ROIC %) | -17.9% | -45.0% | -3.3% |
| Cash & Short-Term Equivalents | $44.8M | $51.4M | $318.4M |
| Total Debt (Short + Long Term) | $26.5M | $94.3M | $677.4M |
| Total Stockholders' Equity | $300.6M | -$859.5M | $1.39B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HTFL.